Details for New Drug Application (NDA): 211724
✉ Email this page to a colleague
The generic ingredient in CAPECITABINE is capecitabine. There is one drug master file entry for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the capecitabine profile page.
Summary for 211724
| Tradename: | CAPECITABINE |
| Applicant: | Reliance Life |
| Ingredient: | capecitabine |
| Patents: | 0 |
Pharmacology for NDA: 211724
| Mechanism of Action | Nucleic Acid Synthesis Inhibitors |
Medical Subject Heading (MeSH) Categories for 211724
Suppliers and Packaging for NDA: 211724
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| CAPECITABINE | capecitabine | TABLET;ORAL | 211724 | ANDA | Lifestar Pharma LLC | 70756-815 | 70756-815-60 | 60 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (70756-815-60) |
| CAPECITABINE | capecitabine | TABLET;ORAL | 211724 | ANDA | Lifestar Pharma LLC | 70756-816 | 70756-816-22 | 120 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (70756-816-22) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 150MG | ||||
| Approval Date: | Apr 27, 2020 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 500MG | ||||
| Approval Date: | Apr 27, 2020 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
